Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 4/8/2026 | $250.00 | Buy | TD Cowen | |
| 3/10/2026 | $180.00 | Buy | Jefferies | |
| 2/20/2026 | $155.00 | Equal Weight | Barclays | |
| 2/11/2026 | $140.00 → $170.00 | Buy | Needham | |
| 1/30/2026 | $49.00 | Neutral → Buy | UBS | |
| 1/28/2026 | $262.00 | Equal-Weight → Overweight | Morgan Stanley | |
| 1/27/2026 | Neutral | Citigroup | ||
| 1/7/2026 | $145.00 | Buy | UBS |
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
4 - GILEAD SCIENCES, INC. (0000882095) (Issuer)
3 - TRINITY BIOTECH PLC (0000888721) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
4 - AIM ImmunoTech Inc. (0000946644) (Issuer)
6-K - GSK plc (0001131399) (Filer)
6-K - GSK plc (0001131399) (Filer)
6-K - GSK plc (0001131399) (Filer)
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy
Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)
As Johnson & Johnson celebrates 30 years of CARTO, the launch of CARTOSOUND SONATA brings new AI-based imaging and mapping capabilitiesi to electrophysiology A total of 17 abstracts will be presented, including new clinical data for the VARIPULSE Platform Johnson & Johnson today announced it will showcase the latest advances across its electrophysiology portfolio at the 2026 Heart Rhythm Society (HRS) Annual Meeting, including new evidence in pulsed field ablation (PFA), and innovations in cardiac mapping and imaging. At HRS 2026, the company will launch the CARTOSOUND SONATA Module, leveraging artificial intelligence with the CARTO System to automatically transform intracardiac echoc
Gilead Sciences, Inc. (NASDAQ:GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. On April 13, 2026, the Australian Competition and Consumer Commission (ACCC) published its decision that the acquisition of Arcellx may be put into effect, subject to expiration of a 14-calendar day waiting period. Assuming that the ACCC's determination remains unchallenged during this waiting period, the waiting period expires at 10:00 a.m., Eastern Time, on April 27, 2026. Additionally, the relevant rev
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Roya
TD Cowen resumed coverage of Johnson & Johnson with a rating of Buy and set a new price target of $250.00
Jefferies initiated coverage of Gilead Sciences with a rating of Buy and set a new price target of $180.00
Barclays initiated coverage of Gilead Sciences with a rating of Equal Weight and set a new price target of $155.00
NEW YORK, March 23, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced the appointment of Lucas Glass as Head of Artificial Intelligence, effective April 2026. Lucas will lead the development and implementation of artificial intelligence capabilities across Royalty Pharma. "Lucas's appointment marks a significant step in our commitment to implementing cutting‑edge technology across our platform," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "By incorporating intelligent automation, advanced analytics and AI-driven decision support, we are strengthening how we evaluate and invest in royalties and support our partners. Luc
NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced an expansion of its leadership team. Greg Butz will join Royalty Pharma as Executive Vice President, Partnering & Investments, effective June 2026. Greg joins Royalty Pharma from Bank of America, where he was the Global Co-Head of Healthcare Investment Banking. "We are thrilled that Greg will join Royalty Pharma and strengthen our leadership team," said Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma. "Greg brings tremendous experience advising healthcare companies on capital raising, strategy, and mergers and acquisitions and he will be a critical addition t
The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (NASDAQ:RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share. The dividend will be paid on June 10, 2026, to shareholders of record at the close of business on May 15, 2026. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Roya
NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (NASDAQ:RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days. About Royalty Pharma Founded in 1996, Royalty Pharma is th
– Additional Commitment will Expand Access to Lenacapavir to Reach Another Million People Over the Next 3 Years – Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. State Department, the United States President's Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund will further invest in Gilead's twice-yearly injectable HIV prevention medicine, lenacapavir, to expand access for up to an additional 1 million people, bringing the total commitment up to 3 million people in high-incidence, resource-limited countries through 2028. Bringing together the resources and expertise of both PEPFAR and The Global Fund is a key component of Gilead's larger coordinated efforts to
SC 13D/A - AIM ImmunoTech Inc. (0000946644) (Subject)
SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)
SC 13G - AIM ImmunoTech Inc. (0000946644) (Subject)